HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Alprostadil

HCID 5280723
New reaction
Print
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
745-65-3
Standard SMILES
CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)O
InChIKey
GMVPRGQOIOIIMI-DWKJAMRDSA-N
Molecular formula
C20H34O5
Average molar mass
354.5 g/mol
Monoisotopic mass
354.24062418

Overview

Prostaglandin E1 is a prostaglandins E. It has a role as a vasodilator agent, an anticoagulant, a platelet aggregation inhibitor and a human metabolite. It is a conjugate acid of a prostaglandin E1(1-).

Names & identifiers

Preferred name
Alprostadil
IUPAC
7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]heptanoic acid
English name
Prostaglandin E1
Molecular formula
C20H34O5
Molecular weight
354.48

Names & synonyms

alprostadilProstaglandin E1745-65-3PGE1CaverjectEdexMuseAlprostadilumBefarProstin VR PediatricVitarosPrink
Show more names
Alprostadil (PGE1)Prost-13-en-1-oic acidProstaglandine E1PGElLiplePalux
PGE-1Prostavasin(11alpha,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acidCaverject ImpulsePGE1alphaDTXSID9022578Lipo PGE1Prostaglandin E1alpha

Database identifiers

CAS
745-65-3
PubChem CID
5280723
DTXSID
DTXSID9022578
ChEMBL
CHEMBL495
ChEBI
CHEBI:15544
UNII
F5TD010360
EC Number
212-017-2
Nikkaji
J3.319G

Properties

Computed structural properties

XLogP
3.2
Topological polar surface area
94.8 Ų
Hydrogen bond donors
3
Hydrogen bond acceptors
5
Rotatable bonds
13
Heavy atoms
25
Formal charge
0
Complexity
432

Experimental & physicochemical properties

DrugsPharmaceuticals -> Listed in ZINC15
LipidsFatty Acyls [FA] -> Eicosanoids [FA03] -> Prostaglandins [FA0301]
LogP3.20
Human Drugs · 2 items

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Melting Point · 2 items

115-116 °C

115 - 116 °C

Physical DescriptionSolid
Dissociation Constants · 2 items

4.87

4.85 (at 25 °C)

Collision Cross Section · 2 items

190.6 Ų [M-H]- [CCS Type: DT; Buffer gas: N2; Ionization: ESI-; Calculation: Single Field; Dataset: Oxylipins]

181.94 Ų [M-H2O-H]- [CCS Type: DT; Method: single field calibrated with Agilent tune mix (Agilent)]

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 4 items

Danger

H301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]

P203, P264, P270, P280, P301+P316, P318, P321, P330, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 74 reports by companies from 5 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Hazard information

Hazard Classes and CategoriesAcute Tox. 3 (100%)

Toxicology

Adverse EffectsAdverse Effects of Intraurethral Alprostadil Suppositories (MUSE)
Toxicity Summary · 1 item

The use of alprostadil for the treatment of erectile dysfunction in males may lead to prolonged erections and, in some cases, priapism. The incidence of priapism as an adverse effect of alprostadil is more common with the intraurethral suppository. This condition can also occur when unauthorized combination therapy is used or when patients exceed the prescribed dosage.

Safety data

F
8-10
wgk
3
rtecs
GY4569800
ridadr
UN 2811 6.1/PG 3
hs_code
29375000
risk_code
22-36/37/38-61
Signal word
Danger

Chemistry & industry

Pharmacology

ATC Code · 5 items

G04BE01

G - Genito urinary system and sex hormones

C - Cardiovascular system

QG - Genito urinary system and sex hormones

QC - Cardiovascular system

Protein BindingAlprostadil is bound in plasma primarily to albumin (81% bound) and, to a lesser extent, alpha-globulin IV-4 fraction (55% bound).
Pharmacodynamics · 1 item

Prostaglandin E1 is produced endogenously to relax vascular smooth muscle and cause vasodilation. As a synthetic form of prostaglandin E1, alprostadil has the same pharmacodynamic effects. Alprostadil inhibits platelet aggregation, has anti-inflammatory effects, interferes with immune responses, and stimulates factor X, a blood coagulation enzyme. In adult males, the use of alprostadil may lead to prolonged erection and priapism, penile fibrosis, hypotension, and injection site bleeding. In patients treated up to 24 months with alprostadil, the incidence of prolonged erections (>4 hours long) was 4% of all, and the incidence of priapism (erections greater than 6 hours in duration) was <1%. Patients with preexisting cardiovascular disease treated with alprostadil may also have higher cardiac risk. Neonates with congenital heart defects treated with alprostadil may experience apnea. Apnea is experienced by 10-12% of neonates and is more common in those weighing less than 2 kg at birth. The administration of alprostadil to neonates may also result in gastric outlet obstruction secondary to antral hyperplasia.

Mechanism of Action · 1 item

Alprostadil is a smooth muscle relaxant that promotes vasodilation and platelet aggregation inhibition. In neonatal patients with ductus arteriosus patency, alprostadil relaxes the ductus arteriosus (DA) smooth muscle, preventing or reversing the functional closure of the DA that occurs shortly after birth. This results in increased pulmonary or systemic blood flow in infants. Alprostadil appears to be most effective within 96 hours after birth since the DA rapidly loses its responsiveness to alprostadil. When administered by intracavernosal injection or as an intraurethral suppository, alprostadil acts locally to relax the trabecular smooth muscle of the corpora cavernosa and the cavernosal arteries. Swelling, elongation, and rigidity of the penis result when arterial blood rapidly flows into the corpus cavernosum to expand the lacunar spaces. The entrapped blood reduces the venous blood outflow as sinusoids compress against the tunica albuginea leading to penile rigidity. This is referred to as the corporal veno-occlusive mechanism.

Related reactions

18 records
New reaction record
HRID 26304 reaction equation
HRID 26304As reactant
HRID 46949 reaction equation
HRID 46949As reactant
HRID 329226 reaction equation
HRID 329226As reactant
HRID 437096 reaction equation
HRID 437096As reactant
HRID 462132 reaction equation
HRID 462132As reactant
HRID 866499 reaction equation
HRID 866499As reactant
HRID 866500 reaction equation
HRID 866500As reactant
HRID 866665 reaction equation
HRID 866665As reactant
PreviousPage 1 of 3

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes

Physicochemical properties

Melting point
115 · 115-116 °C
alpha
-64 · -64 º (c=1.0, C2H5OH)
Boiling point
407.69 °C · 407.69°C (rough estimate)
Density
1.0458 · 1.0458 (rough estimate)
refractive index
1.612 · 1.6120 (estimate)
storage temp.
-20 °C · -20°C
solubility
1 mg/mL · ethanol: 1 mg/mL
pka
4.85 · pKa 4.85± 0.07(H2O,t=25±0.1,I=0.1(NaCl)) (Uncertain)
form
powder
color
White to off-white
biological source
synthetic (organic)
Water Solubility
insoluble
Merck
13 · 13,7968
BRN
5294062 · 5294062
Stability
1 year · Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 1 month.
InChI
1S/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h12-13,15-17,19,21,23H,2-11,14H2,1H3,(H,24,25)/b13-12+/t15-,16+,17+,19+/m0/s1
InChIKey
GMVPRGQOIOIIMI-DWKJAMRDSA-N
SMILES
O=C1[C@H](CCCCCCC(O)=O)[C@@H](/C=C/[C@H](CCCCC)O)[C@H](O)C1
NCI Dictionary of Cancer Terms
1 · alprostadil; PGE1; prostaglandin E1
FDA UNII
5 TD010360 · F5TD010360
NCI Drug Dictionary
alprostadil
ATC code
1 EA01,G04BE01 · C01EA01,G04BE01
UNSPSC Code
41116107 · 41116107
NACRES
77 · NA.77
Symbol(GHS)
6 · GHS06
Signal word
Danger
Hazard statements
301 · H301
Precautionary statements
301 · P301+P310+P330
Hazard Codes
Xn,Xi
Risk Statements
22 · 22-36/37/38-61
Safety Statements
36 · 36-26
RIDADR
2811 · UN 2811 6.1/PG 3
WGK Germany
3 · 3
RTECS
4569800 · GY4569800
F
8 · 8-10
HazardClass
6.1 · 6.1(b)
PackingGroup
III
HS Code
29375000 · 29375000
Storage Class
6.1 C · 6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects
Hazard Classifications
3 Oral · Acute Tox. 3 Oral
Symbol(GHS)
GHS06
hazard_code
Xn,Xi
safety_code
36-26
hazard_class
6.1(b)
Storage Class
6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects
packing_group
III
Hazard statements
H301
Hazard Classifications
Acute Tox. 3 Oral
Precautionary statements
P301+P310+P330
Biological Half-LifeIn healthy adults and neonates given a single intravenous dose of alprostadil, half-life goes from 5 to 10 minutes.
Metabolism/Metabolites · 1 item

Alprostadil is rapidly metabolized in the human body. Following intracavernous administration, alprostadil is metabolized in the corpus cavernosum, and a smaller portion is absorbed from the penis into systemic circulation. After intravenous or arterial administration, alprostadil is metabolized and distributed throughout the entire body except for the central nervous system. As much as 60-90% of the circulating alprostadil may be metabolized in the lungs through first-pass pulmonary elimination, in a process known as beta- and omega-oxidation. The enzymatic oxidation of the C15-hydroxy group of alprostadil leads to the formation of 15-keto-PGE<sub>1</sub>, while the reduction of the C13, 14-double bond produces 15-keto-PGE<sub>0</sub>, and 13,14-dihydro-PGE<sub>1</sub> (PGE<sub>0</sub>). The 15-keto metabolites are inactive, but the PGE<sub>0</sub> metabolite has a similar potency to alprostadil in isolated animal organs. The major metabolite of alprostadil is 15-keto-PGE<sub>0</sub>.

FDA Pharmacological Classification · 6 items

F5TD010360

ALPROSTADIL

Physiologic Effects [PE] - Genitourinary Arterial Vasodilation

Established Pharmacologic Class [EPC] - Prostaglandin Analog

Established Pharmacologic Class [EPC] - Prostaglandin E1 Agonist

Mechanisms of Action [MoA] - Prostaglandin Receptor Agonists

MeSH Pharmacological Classification · 3 items

Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.

Drugs used to cause dilation of the blood vessels.

Drugs used in the treatment of urological conditions and diseases such as URINARY INCONTINENCE and URINARY TRACT INFECTIONS.

Absorption, Distribution and Excretion · 4 items

In patients with erectile dysfunction given 20 μg of alprostadil intracavernously, the systemic plasma concentrations of prostaglandin E1 increased from a baseline of 0.8 pg/mL to a Cmax of 16.8 pg/mL (corrected for baseline). The tmax and AUC for this group of patients were 4.8 min and 173 pg⋅min/mL, respectively. In patients given 20 μg of alprostadil intravenously, AUC was similar to the one detected in patients that received alprostadil intracavernously (174 pg⋅min/mL); however, they had a higher tmax (25.5 min) and a lower Cmax (7.09 pg/mL). Compared to the same dose given by a short-term intravenous infusion, the absolute bioavailability of alprostadil estimated from systemic exposure was about 98%.

Following the degradation of alprostadil by beta- and omega-oxidation, metabolites are excreted primarily by the kidney, and excretion is essentially complete within 24 hours after administration (92%). Approximately 88% and 12% of alprostadil metabolites are excreted through urine and feces, respectively, over 72 hours. Alprostadil and its metabolites are not retained in tissues, and unchanged alprostadil has not been detected in urine.

The volume of distribution of alprostadil has yet to be determined.

In patients with erectile dysfunction given an intravenous infusion of alprostadil (20 μg), the total body clearance was 115 L/min.

Tissue LocationsEpidermis
Cellular LocationsCytoplasm
Applications · 6 items

UsesUsed for diabetic neuropathy, myocardial infarction, thrombotic vasculitis, arteriosclerosis obliterans, central retinal vein thrombosis. It is used in the treatment of hepatitis cirrhosis, cerebral infarction, diabetes, impotence, respiratory diseases. Liver damage is not serious childA, class B patients, especially patients with antithrombin level childA China effect. For induction of labor, oxytocin, renal insufficiency, treatment mumps, pancreatitis. Injection of prostaglandin E1 is mainly applied to myocardial infarction, heart failure, thrombotic vasculitis, chronic arterial occlusive disease, central retinal vein thrombosis, platelet protection for extracorporeal circulation, arteriography, revascularization surgery.

DescriptionProstaglandin E1 is an endogenous prostaglandin with vasodilatory, anti-platelet, and anti-hypertensive activities. It is in clinical use for the treatment of erectile dysfunction and the emergency management of infants with patent ductus arteriosus. It has also been used in the treatment of peripheral arterial occlusive disease (PAD).

UsesFor use in cell culture applications for the study of prostaglandin regulated cell signaling and gene regulation.

UsesA primary Prostaglandin; easily crystallized from purified biological extracts. Vasodilator (peripheral)

UsesVasodilator;Prostaglandin receptor agonist

General DescriptionPGE1, Alprostadil (Prostin VR Pediatric), is a naturally occurring prostaglandin that has found particular use in maintaining a patent (opened) ductus arteriosus in infants with congenital defects that restrict pulmonary or systemic blood flow. Alprostadil must be administered intravenously continually at a rate of approximately 0.1 μg/kg/min to maintain the patency of the ductus arteriosus until corrective surgery can be performed. Up to 80% of circulating alprostadil may be metabolized in a single pass through the lungs. Because apnea has been observed in 10% to 12% of neonates with congenital heart defects, this product should be administered only when ventilatory assistance is immediately available. Other commonly observed side effects include decreased arterial blood pressure, which should be monitored during infusion; inhibited platelet aggregation, which might aggravate bleeding tendencies; and diarrhea.

Upstream & downstream products

Upstream raw materials

2-n-Butoxyethyl methacrylateSilver nitrategamma-Linolenic acid methyl esterGlutathioneCyclopenteneHydrogenArachidonic acidProstaglandin E2Ethyl acetate solutionSodium periodateEthylene glycolSodium Methoxidep-Toluenesulfonic acid monohydratePotassium tert-butoxideSodium hydrideOsmium tetroxideProstaglandin E1 methyl ester(2R,3S)-1,2-Epoxy-3-hydroxy-4-pentene

Additional notes

DefinitionChEBI: Prostaglandin E1 is a prostaglandins E. It has a role as a platelet aggregation inhibitor, a vasodilator agent, an anticoagulant and a human metabolite. It is a conjugate acid of a prostaglandin E1(1-).